Last reviewed · How we verify
Neutral protamine hagedorn insulin
NPH insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
NPH insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Neutral protamine hagedorn insulin |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Intermediate-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
NPH (Neutral Protamine Hagedorn) insulin is a suspension of insulin crystals complexed with protamine, which slows insulin absorption from subcutaneous tissue compared to regular insulin. This results in an intermediate duration of action (10-16 hours) with a peak effect around 4-8 hours. It mimics the basal insulin secretion pattern and is used to control fasting and between-meal blood glucose levels in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- RCT Glargine vs NPH for Treatment of DM in Pregnancy (PHASE3)
- DETERMINE: Detemir vs NPH (PHASE2)
- Comparison of Insulin Glargine and Regular Insulin Versus NPH and Regular Insulin in the Treatment of T1DM (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (PHASE4)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (PHASE4)
- Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy (PHASE4)
- Toujeo Versus NPH Self-titration Study (PHASE4)
- Insulin in Treatment of Diabetes Mellitus With Pregnancy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neutral protamine hagedorn insulin CI brief — competitive landscape report
- Neutral protamine hagedorn insulin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI